FDA 483 - Precision Diabetes Inc. - March 08, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Precision Diabetes Inc., a specification developer of Class II GlycoMark® IVD kits in Raleigh, NC, was inspected by the FDA. The inspection revealed significant deficiencies across multiple quality system areas, indicating a broad breakdown in the firm's quality management system. Observations included a lack of established procedures for design control, corrective and preventive action, nonconforming product, supplier management, acceptance activities, and management review, alongside a failure to perform internal quality audits.
ID · d7cddca2-c595-419c-9449-6b70c3fbe1e4